申请人:Harada Hitoshi
公开号:US20050004149A1
公开(公告)日:2005-01-06
The present invention provides a novel pyrimidine compound having an excellent adenosine receptor (A
1
, A
2A
, A
2B
receptor) antagonistic action. More specifically, it provides a compound represented by the following formula, a salt thereof or a solvate of them.
In the formula, R
1
and R
2
are the same as or different from each other and each represents a hydrogen atom, an alkyl group having one to six carbon atoms which may be substituted, an alkenyl group having two to six carbon atoms which may be substituted, an alkynyl group having two to six carbon atoms which may be substituted, a cycloalkyl group having three to eight carbon atoms which may be substituted, a cycloalkenyl group having three to eight carbon atoms which may be substituted, a 5 to 14-membered non-aromatic heterocyclic group which may be substituted, an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted, an acyl group having one to six carbon atoms which may be substituted or an alkylsulfonyl group having one to six carbon atoms which may be substituted; R
3
represents a hydrogen atom, a halogen atom, a cyano group, an alkyl group having one to six carbon atoms which may be substituted, an alkenyl group having two to six carbon atoms which may be substituted, an alkynyl group having two to six carbon atoms which may be substituted, an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted, a nitrogen atom which may be substituted, an oxygen atom which may be substituted or a sulfur atom which may be substituted; R
4
represents an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted or a 5 to 14-membered non-aromatic heterocyclic group having at least one or more unsaturated bonds which may be substituted; and R
5
represents an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted or a 5 to 14-membered aromatic heterocyclic group which may be substituted.
本发明提供了一种新型嘧啶化合物,具有优异的腺苷受体(A1、A2A、A2B受体)拮抗作用。更具体地,提供了下式所示的化合物、其盐或其溶剂化物。其中,R1和R2相同或不同,分别代表氢原子、可被取代的具有1至6个碳原子的烷基、可被取代的具有2至6个碳原子的烯基、可被取代的具有2至6个碳原子的炔基、可被取代的具有3至8个碳原子的环烷基、可被取代的具有3至8个碳原子的环烯基、可被取代的5至14个成员的非芳香杂环基、可被取代的具有6至14个碳原子的芳香烃环基、可被取代的5至14个成员的芳香杂环基、可被取代的具有1至6个碳原子的酰基或可被取代的具有1至6个碳原子的烷基磺酰基;R3代表氢原子、卤素原子、氰基、可被取代的具有1至6个碳原子的烷基、可被取代的具有2至6个碳原子的烯基、可被取代的具有2至6个碳原子的炔基、可被取代的具有6至14个碳原子的芳香烃环基、可被取代的5至14个成员的芳香杂环基、可被取代的氮原子、可被取代的氧原子或可被取代的硫原子;R4代表可被取代的具有6至14个碳原子的芳香烃环基、可被取代的5至14个成员的芳香杂环基或可被取代的具有至少一个或多个不饱和键的5至14个成员的非芳香杂环基;而R5代表可被取代的具有6至14个碳原子的芳香烃环基或可被取代的5至14个成员的芳香杂环基。